VitalConnect Inc. is more than $30 million richer these days, having closed an oversubscribed Series F financing found.  The funding was provided by Revelation Partners as well as existing investors including Pacific General Ventures and EW Healthcare Partners.

目前，VitalConnect Inc.拥有超过3000万美元的富裕资金，已经关闭了一个过度转录的F系列融资。该资金由Revelation合作伙伴以及包括Pacific General Ventures和EW Healthcare合作伙伴在内的现有投资者提供。

“Revelation Partners is excited to join the list of VitalConnect investors to help further accelerate the company’s growth,” said Fred Lee, a partner at Revelation Partners.  “VitalConnect is in the unique position of being able to participate in multiple billion-dollar markets that are growing at double-digit rates.

Revelation Partners的合作伙伴Fred Lee说：“Revelation Partners很高兴加入VitalConnect投资者名单，以帮助进一步加速公司的发展。”。“VitalConnect处于独特的地位，能够参与以两位数利率增长的数十亿美元市场。

The adoption of the technology in the marketplace, thus far, has been unprecedented, thereby giving us confidence in the leadership team’s ability to execute. We are committed to supporting the organization to enable them to maximize both revenue and profitability.”.

到目前为止，该技术在市场上的应用是前所未有的，从而使我们对领导团队的执行能力充满信心。我们致力于支持组织，使他们能够最大限度地增加收入和盈利能力。”。

The money will help support VitalConnect’s remote cardiac monitoring business and advance key partnerships with the largest U.S. hospital systems to provide remote patient monitoring in an in-patient setting.

该资金将有助于支持VitalConnect的远程心脏监测业务，并推进与美国最大的医院系统的关键合作伙伴关系，以便在住院环境中提供远程患者监测。

“VitalConnect’s services have been widely adopted at an accelerated pace over the past 24 months, enabling our revenue to triple from 2021 to 2022, and putting us on track to nearly double revenue again in 2023.  We are also experiencing significant EBITDA improvement and we expect to achieve profitability in 2024,” VitalConnect CEO Peter Van Haur stated.  “This latest round of financing, at an increased valuation, signals unwavering support from our investors while providing the company the runway needed to achieve our goal of being the world’s leading provider of remote patient monitoring solutions.” .

“VitalConnect的服务在过去24个月中以加速的速度被广泛采用，使我们的收入从2021年增加到2022年，使我们的收入增加了两倍，并使我们在2023年再次实现近两倍的收入。我们也正在经历显着的EBITDA改进，我们期望在2024年实现盈利，“VitalConnect首席执行官Peter Van Haur说。“最新一轮融资以更高的估值，标志着我们投资者的坚定支持，同时为公司提供实现我们成为全球领先的远程患者监控解决方案提供商目标所需的跑道。”。.

Founded in 2011, VitalConnect has deployed hundreds of thousands of biosensors worldwide, including at leading healthcare facilities such as Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital-Oxford University. The VitalPatch allows real-time remote or in-hospital monitoring, allowing physicians to optimize the delivery of care to their patients. .

VitalConnect成立于2011年，在全球范围内部署了数十万个生物传感器，其中包括布莱根妇女医院，哈肯萨克医疗中心，Northwell Health和牛津大学John Radcliffe医院等领先的医疗机构。VitalPatch允许实时远程或院内监测，使医生能够优化向患者提供护理。。.

VitalConnect develops wearable biosensor technology for wireless patient monitoring in both hospital and remote patient populations. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms that achieve better health and economic outcomes.

VitalConnect开发可穿戴式生物传感器技术，用于医院和远程患者群体的无线患者监测。它利用生物医学工程，数据分析，芯片设计以及移动和云软件方面的广泛专业知识来创建支持决策范例的技术，以实现更好的健康和经济成果。

The firms products are designed for use in various inpatient and outpatient settings, such as hospital monitoring, post-discharge care, cardiac monitoring and pharmaceutical solutions. VitalConnect’s advanced, yet easy-to-use, platform, was designed to deliver better healthcare at lower costs while providing more convenience for the patients and healthcare providers.   .

firms产品设计用于各种住院和门诊环境，如医院监测，出院后护理，心脏监测和药物解决方案。VitalConnect先进且易于使用的平台旨在以更低的成本提供更好的医疗保健，同时为患者和医疗保健提供者提供更多便利。  。.

Revelation Partners provides flexible capital solutions to the healthcare ecosystem. These customized solutions provide liquidity, align shareholders, and support the growth of privately-held healthcare companies. The firm’s long-term approach allows it to address the issues faced by a wide range of counterparties, including founders, company management teams, institutional investors (including general partners), and limited partners.   .

启示合作伙伴为医疗保健生态系统提供灵活的资本解决方案。这些定制的解决方案提供流动性，调整股东，并支持私营医疗保健公司的发展。该公司的长期方法使其能够解决广泛的对手所面临的问题，包括创始人，公司管理团队，机构投资者（包括一般合作伙伴）和有限合作伙伴。   .